文献速递乳腺癌

简化乳腺磁共振成像用于致密乳腺及平均风险女性的补充筛查

Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
PubMed 文献 · J Clin Oncol · 2020-09-15

该研究回顾性分析了475例致密乳腺且平均风险的无症状女性,在数字乳腺断层摄影(DBT)阴性/良性后行简化乳腺磁共振成像(AB-MR)补充筛查。患者水平癌症检出率(CDR)为27.4/1000(13/475,95%CI 16.1–46.3),活检恶性率为30.8%(12/39),浸润癌均无腋窝淋巴结阳性,1年随访无 interval cancer。

要点

  • 致密乳腺女性DBT阴性后补充AB-MR,CDR达27.4/1000。
  • 活检恶性率30.8%,浸润癌均≤1.0 cm且无淋巴结阳性。
  • 1年随访无 interval cancer,支持进一步评估AB-MR筛查价值。

核心结论

  • 在致密乳腺且平均风险女性中,DBT阴性/良性后补充AB-MR筛查的患者水平CDR为27.4/1000(13/475,95%CI 16.1–46.3)。
  • 初步结果支持进一步评估AB-MR作为补充筛查手段。

研究设计与样本

  • 回顾性临床实施研究,经机构审查委员会批准并符合HIPAA。
  • 纳入2016年1月1日至2019年2月28日期间接受AB-MR筛查的475例无症状致密乳腺女性,此前DBT为阴性/良性。
  • AB-MR使用1.5T磁体,协议包括STIR、平扫和增强序列,生成减影和最大强度投影图像。

主要发现

  • 475例中,420例(88.4%)为良性/阴性,13例(2.7%)建议随访,42例建议活检。
  • 完成39例活检,12例(30.8%)为恶性:7例浸润癌和5例导管原位癌。
  • 另1例在6个月随访时诊断为浸润性导管癌。
  • 浸润癌大小范围0.6–1.0 cm(均值0.5 cm),7例接受腋窝手术评估者均无阳性淋巴结。
  • 1年随访无 interval cancer。

关键数值与推荐

  • 患者水平CDR为27.4/1000(13/475,95%CI 16.1–46.3)。
  • 活检恶性率为30.8%(12/39)。
  • 浸润癌大小范围0.6–1.0 cm(均值0.5 cm),7例腋窝评估均阴性。

临床怎么用

  • 对于致密乳腺且平均风险女性,DBT阴性后可考虑补充AB-MR筛查以提高癌症检出。
  • AB-MR筛查发现的浸润癌多体积小且淋巴结阴性,可能有助于早期诊断。

局限性

  • 回顾性研究设计。
  • 样本量有限(475例),需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although mammography is the standard of care for breast cancer screening, dense breast tissue decreases mammographic sensitivity. We report the prevalent cancer detection rate (CDR) from the first clinical implementation of abbreviated breast magnetic resonance imaging (AB-MR) as a supplemental screening test in women with dense breasts. METHODS: The study was approved by the institutional review board and is Health Insurance Portability and Accountability Act complaint. This retrospective review includes women who were imaged between January 1, 2016 and February 28, 2019. On a 1.5 Tesla magnet, the imaging protocol consisted of three sequences: Short-TI Inversion Recovery (STIR), precontrast, and postcontrast. A subtraction sequence and a maximum intensity projection were generated. We report the patient-level CDR and the positive predictive value of AB-MR examinations after negative/benign digital breast tomosynthesis (DBT). RESULTS: Out of 511 prevalent rounds of AB-MR examinations, 36 women were excluded. The remaining 475 asymptomatic women with dense breasts had negative/benign DBT examinations before the AB-MR. There were 420 of 475 (88.4%) benign/negative examinations, 13 of 475 (2.7%) follow-up recommendations, and 42 biopsy recommendations. Thirty-nine biopsies were completed, resulting in 12/39 (30.8%) malignancies in 12 women: seven invasive carcinomas and five ductal carcinoma in situ. One additional patient was diagnosed with invasive ductal carcinoma at the time of 6-month follow-up. The CDR was 27.4 per 1,000 (13 of 475; 95% CI, 16.1 to 46.3). The size of invasive carcinomas ranged from 0.6-1.0 cm (mean, 0.5 cm). Of the seven women who underwent surgical evaluation of the axilla, zero of seven patients had positive nodes. There were no interval cancers at 1-year follow-up. CONCLUSION: Preliminary results from clinical implementation of screening AB-MR resulted in a CDR of 27.4/1,000 at the patient level after DBT in women with dense breasts. Additional evaluation is warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Weinstein SP, Korhonen K, Cirelli C, et al. Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk. J Clin Oncol. 2020. PMID: 32931396. doi:10.1200/JCO.19.02198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。